幹細胞治療市場規模、シェア、動向、2035年までの世界予測

幹細胞治療市場は2026年に4億8,000万米ドル規模となり、2026年から2035年までに年平均成長率（CAGR）25.3%で成長し、2035年には36億5,000万米ドルに成長するとMarketsandMarketsでは予測しています。

この市場は、幹細胞を用いた治療法の開発パイプラインの拡大、再生医療への需要増加、iPSC由来治療や同種細胞製品といった先進的な治療法の成長によって牽引されています。市場予測では、細胞処理・製造技術の進歩と承認済み幹細胞治療の臨床応用拡大に支えられ、2035年まで力強い成長が見込まれています。しかしながら、製造・治療コストの高さ、地域ごとの複雑な規制手続き、基礎研究から商業生産へのスケールアップの課題、専門的なインフラと専門知識の必要性などが、市場全体の成長を抑制する要因となることが予想されます。

MarketsandMarkets（マーケッツアンドマーケッツ）「幹細胞治療市場 – 細胞源（脂肪組織、骨髄、胎盤、臍帯、iPSC）、種類（自家幹細胞）、治療用途（筋骨格系、創傷、手術、心血管系、神経系）、エンドユーザー – 2035年までの世界予測 – Stem Cell Therapy Market by Cell Source (Adipose Tissue, Bone Marrow, Placenta, Umbilical Cord, iPSC), Type (Autologus Stem Cell), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological), End User – Global Forecast to 2035」は幹細胞治療の世界市場を調査し、主要セグメント別に分析・予測を行っています。

調査対象セグメント

• 細胞源別幹細胞治療市場
  • 脂肪組織由来間葉系幹細胞
  • 骨髄由来間葉系幹細胞
  • 胎盤／臍帯由来間葉系幹細胞
  • 誘導多能性幹細胞（iPSC）
  • 胚性幹細胞（ESC）
  • 組織特異的幹細胞
  • その他の細胞源
• 種類別幹細胞治療市場
  • 同種幹細胞療法
  • 自家幹細胞療法
• 治療用途別幹細胞治療市場
  • 筋骨格系疾患
  • 創傷と手術
  • 炎症性疾患と自己免疫疾患
  • 心血管疾患
  • 神経疾患
  • 糖尿病および代謝性疾患
  • その他の治療用途
• エンドユーザ別幹細胞治療市場
  • 病院
  • 専門／幹細胞クリニック
  • その他のエンドユーザ
• 地域別幹細胞治療市場
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他のアジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ
  • 中東
    • GCC諸国
      • サウジアラビア
      • アラブ首長国連邦（UAE）
      • その他のGCC諸国
    • その他の中東
  • アフリカ

調査対象企業

• Vericel Corporation (米国)
• Mesoblast (オーストラリア)
• MEDIPOST (韓国)
• JCRファーマ株式会社  (日本)
• 武田薬品工業株式会社 (日本)
• Anterogen Co., Ltd. (韓国)
• CorestemChemon Inc. / Corestem, Inc. (韓国)
• Vertex Pharmaceuticals (米国)
• Pharmicell Co., Ltd. (韓国)
• Holostem Terapie Avanzate Srl (イタリア)
• Stempeutics Research Pvt. Ltd. (インド)
• Cipla Limited (インド)
• Bayer AG (ドイツ)
• Aspen Neuroscience (米国)
• Longeveron Inc. (米国)
• Smith+Nephew (英国)

調査範囲

本調査レポートは、幹細胞治療市場を、細胞源（脂肪組織由来間葉系幹細胞、骨髄由来間葉系幹細胞、胎盤／臍帯由来間葉系幹細胞、誘導多能性幹細胞、胚性幹細胞、組織特異的幹細胞、その他の細胞源）、種類（同種幹細胞療法、自家幹細胞療法）、治療用途（筋骨格系疾患、創傷・手術、炎症性疾患・自己免疫疾患、心血管疾患、神経疾患、糖尿病・代謝性疾患、その他の治療用途）、エンドユーザー（病院、専門／幹細胞クリニック、その他のエンドユーザー）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ）別に分類しています。

本レポートは、幹細胞治療市場の成長に影響を与える主要な要因（推進要因、課題、機会、制約など）に関する詳細な情報を網羅しています。主要な業界プレーヤーの詳細な分析を行い、事業概要、製品ポートフォリオ、製品・サービスの承認・発売、提携、パートナーシップ、事業拡大、契約、幹細胞治療市場に関連する最近の動向といった主要戦略に関する洞察を提供します。本レポートは、幹細胞治療市場のエコシステムにおける主要プレーヤーと新興スタートアップの競合分析を網羅しています。

レポート購入の主なメリット

本レポートは、幹細胞治療市場全体およびそのサブセグメントの収益に関する最も正確な予測を提供することで、市場リーダーや新規参入企業を支援します。また、関係者が競争環境をより深く理解し、事業をより効果的に位置づけ、適切な市場参入戦略を策定するための洞察を得るのに役立ちます。本レポートは、関係者が市場の動向を把握し、主要な市場推進要因、制約、機会、課題に関する情報を得ることを可能にします。

本レポートは、以下のポイントに関する洞察を提供します。

主要な推進要因の分析（規制当局の承認件数の増加により、幹細胞療法が商業的に実現可能な治療法として確立されつつある。希少疾患および慢性疾患における満たされていないニーズの高さが、根治的治療への需要を高めている。遺伝子改変HSPC療法は、幹細胞療法市場において高付加価値セグメントを創出している。同種移植および既製製剤のアプローチは、自家移植療法に比べて拡張性を向上させている）、阻害要因の分析（高額な治療費と不確実な償還制度が市場導入における最大の阻害要因であり、製造の複雑さと高コストが拡張性と利益率を制限している。一部の再生医療適応症における臨床的エビデンスの不一致が、支払者と医師の信頼を低下させている。各国間の規制の多様性が、グローバルな商業化を複雑にしている）、機会の分析（iPSC由来療法は、拡張可能な細胞置換療法の長期的な機会を提供する。同種MSCおよび前駆細胞プラットフォームは、個別化治療を超えてアクセスを拡大できる。神経系、心血管系、代謝系、および眼疾患は市場の可能性を広げ、遺伝子改変HSPC療法はより若い患者、その他のヘモグロビン異常症、免疫疾患、代謝性疾患にも適用範囲を拡大できる可能性があります。また、課題も存在します（効力試験や製品特性評価の課題、多様な再生医療適応症における明確な臨床効果の実証の難しさ、プロセス変更後の製造上の互換性がスケールアップや承認を遅らせる可能性、患者の紹介、適格性、治療準備が実際の普及を遅らせる可能性など）。

• 製品開発／イノベーション：世界の幹細胞治療市場における今後の技術と研究開発活動に関する詳細な洞察
• 市場開発：有望な市場に関する包括的な情報（本レポートは様々な地域における市場を分析しています）
• 市場の多様化：世界の幹細胞治療市場における未開拓地域、最近の動向、投資に関する包括的な情報
• 競合評価：主要企業の市場シェア、成長戦略、製品提供に関する詳細な評価（主要企業の詳細な分析を実施し、主要戦略、製品に関する洞察を提供しています） （世界の幹細胞治療市場における新製品発売／承認、買収、提携、契約、協力、その他の最近の動向、投資および資金調達活動、ブランド／製品比較分析、ベンダー評価および財務指標）

Report Description

The stem cell therapy market is projected to reach USD 3.65 billion by 2035 from USD 0.48 billion in 2026, at a CAGR of 25.3% from 2026 to 2035. The market is driven by the expanding pipeline of stem cell-based therapies, increasing demand for regenerative treatments, and growth in advanced modalities such as iPSC-derived therapies and allogeneic cell products. Market estimates indicate robust expansion through 2035, supported by technological advancements in cell processing and manufacturing and rising clinical adoption of approved stem cell therapies. However, high manufacturing and treatment costs, complex regulatory pathways across regions, scalability challenges from bench to commercial manufacturing, and the need for specialized infrastructure and expertise are expected to restrain broader market growth.

“The induced pluripotent stem cell (iPSC) segment is projected to grow at the highest CAGR in the stem cell therapy market over the forecast period.”

Based on cell source, the stem cell therapy market is broadly segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, induced pluripotent stem cells, embryonic stem cells, tissue-specific stem cells, and other cell sources. The induced pluripotent stem cell (iPSC) segment is expected to grow at the highest CAGR in the stem cell therapy market because it is moving from a high-potential research platform toward early commercial validation, while still starting from a relatively low revenue base. iPSCs provide a renewable and scalable cell source that can be differentiated into multiple therapeutic cell types, including dopaminergic neurons, cardiomyocytes, retinal cells, pancreatic beta-like cells, and other tissue-specific cells, making them attractive for large unmet-need indications such as Parkinson’s disease, heart failure, diabetes, retinal disorders, and other degenerative diseases.

“Allogeneic stem cell therapy accounted for the largest share of the stem cell therapy market, by type, in 2025.”

Based on type, the global stem cell therapy market is segmented into allogeneic and autologous stem cell therapies. The allogeneic stem cell therapy segment accounted for the largest share of the stem cell therapy market in 2025, due to its scalability, off-the-shelf availability, and cost advantages in commercial manufacturing. These therapies enable standardized production and broader patient access essential for clinical and commercial applications. Additionally, the expanding pipeline of allogeneic cell therapy candidates, increasing regulatory approvals, and growing commercial-scale manufacturing activities continue to strengthen the segment’s leading market position globally.

“Europe is projected to grow at the highest CAGR in the stem cell therapy market from 2026 to 2035.”

The stem cell therapy market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, Europe is projected to be the fastest-growing region in the stem cell therapy market due to its strong regulatory framework for advanced therapy medicinal products, expanding transplant and cell therapy infrastructure, high clinical trial activity, and rising investment in scalable ATMP manufacturing. The EMA classifies substantially manipulated or non-homologous stem-cell products as ATMPs and has a dedicated Committee for Advanced Therapies, creating a clear pathway for stem cell-based product assessment, scientific advice, and market authorization.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)

List of Companies Profiled in the Report

Key players in the global stem cell therapy market include Vericel Corporation (US), Mesoblast (Australia), MEDIPOST (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Anterogen Co., Ltd. (South Korea), CorestemChemon Inc. / Corestem, Inc. (South Korea), Vertex Pharmaceuticals (US), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate Srl (Italy), Stempeutics Research Pvt. Ltd. (India), Cipla Limited (India), Bayer AG (Germany), Aspen Neuroscience (US), Longeveron Inc. (US), and Smith+Nephew (UK).

Research Coverage

This research report categorizes the stem cell therapy market by Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Placenta/Umbilical Cord-Derived Mesenchymal Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, Tissue-Specific Stem Cells, Other Cell Sources), Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), Therapeutic Application (Musculoskeletal Disorders, Wounds & Surgeries, Inflammatory & Autoimmune Diseases, Cardiovascular Diseases, Neurological Disorders, Diabetes & Metabolic Diseases, Other Therapeutic Applications), End User (Hospitals, Specialty / Stem Cell Clinics, Other End Users), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa)

The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the stem cell therapy market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the stem cell therapy market. This report covers competitive analysis of top players and upcoming startups in the stem cell therapy market ecosystem.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall stem cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (rising regulatory approvals are validating stem cell therapy as a viable commercial treatment class, high unmet needs in rare and chronic diseases are driving demand for curative therapies, gene-modified HSPC therapies are creating a high-value segment in the stem cell therapy market, allogeneic and off-the-shelf approaches are improving scalability over autologous therapies), restraints (high therapy price and uncertain reimbursement remain the largest restraints on market adoption, manufacturing complexity and high cost of goods limit scalability and margins, inconsistent clinical evidence in some regenerative indications reduces payer and physician confidence, regulatory heterogeneity across countries complicates global commercialization.), opportunities (iPSC-derived therapies offer long-term opportunities for scalable cell replacement, allogeneic MSC and progenitor-cell platforms can expand access beyond individualized therapy, expansion into neurological, cardiovascular, metabolic, and ocular diseases can broaden market potential, Gene-modified HSPC therapies can expand into younger patients, additional hemoglobinopathies, immune diseases, and metabolic diseases), and challenges (potency testing and product characterization challenges, demonstrating clear clinical efficacy is difficult in heterogeneous regenerative indications, manufacturing comparability after process changes can delay scale-up and approval, patient referral, eligibility, and treatment readiness can slow real-world uptake

• Product Development/Innovation: Detailed insights into upcoming technologies and research & development activities in the global stem cell therapy market
• Market Development: Comprehensive information about lucrative markets (the report analyzes the market across varied regions)
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the global stem cell therapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players (a detailed analysis of the key industry players has been carried out to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investments & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the global stem cell therapy market)

Table of Contents

1 INTRODUCTION 30

1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 MARKETS SEGMENTATION AND REGIONAL SCOPE 31
1.4 INCLUSIONS & EXCLUSIONS 32
1.4.1 YEARS CONSIDERED 32
1.4.2 CURRENCY CONSIDERED 33
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHNAGES 33

2 EXECUTIVE SUMMARY 35

2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 35
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 37
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 38
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 39
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 40

3 PREMIUM INSIGHTS 41

3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN STEM CELL THERAPY MARKET 41
3.2 STEM CELL THERAPY MARKET, BY TYPE AND REGION 42
3.3 STEM CELL THERAPY MARKET, BY COUNTRY 42
3.4 STEM CELL THERAPY MARKET SHARE, BY TYPE, 2026 VS 2035 43

4 MARKET OVERVIEW 44

4.1 INTRODUCTION 44
4.2 MARKET DYNAMICS 44
4.2.1 DRIVERS 45
4.2.1.1 Rising regulatory approvals validating stem cell therapies 45
4.2.1.2 Unmet needs in rare and chronic diseases driving demand for curative therapies 46
4.2.1.3 Allogeneic and off-the-shelf approaches improving scalability over autologous therapies 46
4.2.2 RESTRAINTS 46
4.2.2.1 High therapy price and uncertain reimbursement limiting adoption 46
4.2.2.2 Manufacturing complexity and high cost of goods limiting
scalability and margins 47
4.2.2.3 Inconsistent clinical evidence reducing payer and physician confidence 47
4.2.2.4 Regulatory inconsistency across countries complicating
global commercialization 48
4.2.3 OPPORTUNITY 48
4.2.3.1 iPSC-derived therapies offering long-term opportunities for
scalable cell replacement 48
4.2.3.2 Allogeneic MSC and progenitor-cell platforms can support expansion beyond personalized treatment models 48
4.2.3.3 Expansion into neurological, cardiovascular, and metabolic diseases 49
4.2.4 CHALLENGES 49
4.2.4.1 Potency testing and product characterization challenges 49
4.2.4.2 Difficulty in demonstrating clear clinical efficacy in heterogeneous regenerative indications 49
4.2.4.3 Manufacturing comparability challenges following process changes may delay scale-up and regulatory approval 49
4.3 UNMET NEEDS AND WHITE SPACES 50
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 50
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 51

5 INDUSTRY TRENDS 52

5.1 PORTER’S FIVE FORCES ANALYSIS 52
5.1.1 THREAT OF NEW ENTRANTS 53
5.1.2 THREAT OF SUBSTITUTES 53
5.1.3 BARGAINING POWER OF BUYERS 53
5.1.4 BARGAINING POWER OF SUPPLIERS 53
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 54
5.2 MACROECONOMIC OUTLOOK 54
5.2.1 INTRODUCTION 54
5.2.2 GDP TRENDS AND FORECAST 55
5.2.3 TRENDS IN GLOBAL STEM CELL THERAPY MARKET 55
5.2.4 TRENDS IN GLOBAL STEM CELL THERAPY MARKET 55
5.3 VALUE CHAIN ANALYSIS 56
5.4 ECOSYSTEM ANALYSIS 58
5.5 PRICING ANALYSIS 59
5.5.1 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT 59
5.5.2 INDICATIVE SELLING PRICE, BY REGION 60
5.6 KEY CONFERENCES & EVENTS 61
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 62
5.8 INVESTMENT/FUNDING ACTIVITY 62
5.9 CASE STUDY ANALYSIS 63
5.10 IMPACT OF 2025 US TARIFF – STEM CELL THERAPY MARKET 64
5.10.1 INTRODUCTION 64
5.10.2 KEY TARIFF RATES 64
5.10.3 PRICE IMPACT ANALYSIS 65
5.10.4 IMPACT ON COUNTRY/REGION 66
5.10.4.1 North America 66
5.10.4.2 Europe 66
5.10.4.3 Asia Pacific 67
5.10.5 IMPACT ON END-USE INDUSTRIES 67
5.10.5.1 Hospitals 67
5.10.5.2 Specialty/Stem cell clinics 68
5.10.5.3 Other end users 68
5.11 SUPPLY CHAIN ANALYSIS 68
5.12 KEY STEM CELL THERAPY MANUFACTURING CAPACITY ADDITIONS 70
5.12.1 KEY CDMO CAPACITY ADDITIONS 70
5.12.2 KEY SPONSOR CAPACITY ADDITIONS 70
5.12.3 GLOBAL KEY STEM CELL THERAPY PRODUCT SALES 72
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS 73

6.1 TECHNOLOGY ANALYSIS 73

6.1.1 KEY TECHNOLOGIES 73
6.1.1.1 Bioreactor systems 73
6.1.1.2 Cell expansion & differentiation platforms 73
6.1.2 ADJACENT TECHNOLOGIES 73
6.1.2.1 Reprogramming & gene engineering tools 73
6.1.2.2 Downstream processing technologies 73
6.1.3 COMPLEMENTARY TECHNOLOGIES 74
6.1.3.1 Advanced cell culture consumables 74
6.1.3.2 Automation and robotics 74
6.2 TECHNOLOGY/PRODUCT ROADMAP 74
6.3 PIPELINE ANALYSIS 74
6.4 FUTURE APPLICATIONS 77
6.5 IMPACT OF AI/GEN AI ON STEM CELL THERAPY MARKET 77
6.5.1 TOP USE CASES AND MARKET POTENTIAL 78
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN STEM CELL THERAPY MARKET 78
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 78
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN STEM CELL THERAPY MARKET 79
6.6 SUCCESS STORIES AND REAL WORLD APPLICATIONS 80

7 SUSTAINABILITY AND REGULATORY LANDSCAPE 81

7.1 REGIONAL REGULATIONS AND COMPLIANCE 81
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
7.1.2 REGULATORY FRAMEWORK 84
7.1.3 INDUSTRY STANDARDS 84
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 85
7.3 CERTIFICATIONS, LABELING & ECO-STANDARDS 85

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 88

8.1 DECISION-MAKING PROCESS 88
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 89
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 89
8.2.2 KEY BUYING CRITERIA, BY END USER 89
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 91
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 91
8.5 MARKET PROFITABILITY 92

9 STEM CELL THERAPY MARKET BY CELL SOURCE 93

9.1 INTRODUCTION 94
9.2 ADIPOSE TISSUE-DERIVED MSCS 94
9.2.1 GROWING ADOPTION OF ADIPOSE-DERIVED MSC THERAPIES IN RECONSTRUCTIVE SURGERY AND AESTHETIC MEDICINE DRIVING MARKET 94
9.3 BONE MARROW-DERIVED MSCS 97
9.3.1 ACCELERATING REGULATORY MILESTONES AND EXPANDING INDICATIONS FOR BONE MARROW-DERIVED MSC THERAPIES DRIVING MARKET GROWTH 97
9.4 PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS 100
9.4.1 EXPANDING CORD BLOOD BANKING INFRASTRUCTURE AND ALLOGENEIC PRODUCT DEVELOPMENT FUELING SEGMENT GROWTH 100
9.5 INDUCED PLURIPOTENT STEM CELLS (IPSCS) 102
9.5.1 BREAKTHROUGH CLINICAL PROGRAMS AND NEXT-GENERATION MANUFACTURING PLATFORMS POSITIONING IPSCS AS TRANSFORMATIVE CELL SOURCE 102
9.6 EMBRYONIC STEM CELLS (ESCS) 105
9.6.1 LANDMARK REGULATORY APPROVALS AND CLINICAL VALIDATION OF
ESC-DERIVED ISLET CELL THERAPIES CATALYZING GROWTH 105
9.7 TISSUE-SPECIFIC STEM CELLS 108
9.7.1 ESTABLISHED COMMERCIAL PRODUCTS AND EXPANDING CLINICAL APPLICATIONS FUELING MARKET GROWTH 108
9.8 OTHER CELL SOURCES 110

10 STEM CELL THERAPY MARKET BY TYPE 113

10.1 INTRODUCTION 114
10.2 ALLOGENEIC STEM CELL THERAPY 114
10.2.1 SCALABLE OFF-THE-SHELF MANUFACTURING AND EXPANDING CLINICAL PIPELINES DRIVING RAPID GROWTH 114
10.3 AUTOLOGOUS STEM CELL THERAPY 117
10.3.1 ESTABLISHED COMMERCIAL PRODUCTS AND PATIENT-SPECIFIC IMMUNOLOGICAL ADVANTAGES TO SUSTAIN STEADY GROWTH 117

11 STEM CELL THERAPY MARKET BY THERAPEUTIC APPLICATION 120

11.1 INTRODUCTION 121
11.2 MUSCULOSKELETAL DISORDERS 121
11.2.1 RISING GLOBAL PREVALENCE OF OSTEOARTHRITIS AND GROWING ADOPTION OF CELL-BASED CARTILAGE REPAIR THERAPIES DRIVING SEGMENT GROWTH 121
11.3 WOUNDS & SURGERIES 124
11.3.1 EXPANDING APPLICATIONS OF STEM CELL THERAPIES IN WOUND HEALING, BURN TREATMENT, AND SURGICAL RECONSTRUCTION SUPPORTING SEGMENT GROWTH 124
11.4 INFLAMMATORY & AUTOIMMUNE DISEASES 127
11.4.1 EXPANDING CLINICAL VALIDATION OF MSC IMMUNOMODULATORY PROPERTIES AND FDA APPROVAL OF RYONCIL FOR GVHD DRIVING GROWTH 127
11.5 CARDIOVASCULAR DISEASES 129
11.5.1 ADVANCING LATE-STAGE CLINICAL PROGRAMS AND GROWING EVIDENCE FOR MSC-MEDIATED CARDIAC REPAIR SUPPORTING MARKET GROWTH 129
11.6 NEUROLOGICAL DISORDERS 132
11.6.1 BREAKTHROUGH IPSC-DERIVED NEURONAL THERAPIES AND EXPANDING CLINICAL PROGRAMS FOR NEURODEGENERATIVE CONDITIONS DRIVING SEGMENTAL GROWTH 132
11.7 DIABETES & METABOLIC DISEASES 135
11.7.1 TRANSFORMATIVE POTENTIAL OF ESC-DERIVED ISLET CELL THERAPIES FOR TYPE 1 DIABETES FUELING RAPID MARKET GROWTH 135
11.8 OTHER THERAPEUTIC APPLICATIONS 137

12 STEM CELL THERAPY MARKET, BY END USER 140

12.1 INTRODUCTION 141
12.2 HOSPITALS 141
12.2.1 ADVANCED TRANSPLANT INFRASTRUCTURE AND CONCENTRATION OF REGULATORY-APPROVED STEM CELL THERAPY ADMINISTRATION
DRIVING GROWTH 141
12.3 SPECIALTY/STEM CELL CLINICS 144
12.3.1 GROWING NUMBER OF DEDICATED REGENERATIVE MEDICINE CENTERS
AND EXPANDING AUTOLOGOUS MSC TREATMENT OFFERINGS DRIVING SEGMENTAL GROWTH 144
12.4 OTHER END USERS 146
12.4.1 AMBULATORY SURGICAL CENTERS, ACADEMIC RESEARCH INSTITUTES,
AND CELL BANKS EXPANDING STEM CELL THERAPY DELIVERY ECOSYSTEM 146

13 STEM CELL THERAPY MARKET, BY REGION 150

13.1 INTRODUCTION 151
13.2 NORTH AMERICA 151
13.2.1 US 154
13.2.2 CANADA 155

13.3 EUROPE 157
13.3.1 GERMANY 160
13.3.2 UK 161
13.3.3 FRANCE 163
13.3.4 ITALY 164
13.3.5 SPAIN 166
13.3.6 REST OF EUROPE 167
13.4 ASIA PACIFIC 169
13.4.1 CHINA 171
13.4.2 JAPAN 172
13.4.3 INDIA 174
13.4.4 SOUTH KOREA 175
13.4.5 AUSTRALIA 177
13.4.6 REST OF ASIA PACIFIC 178
13.5 LATIN AMERICA 180
13.5.1 BRAZIL 182
13.5.2 MEXICO 183
13.5.3 REST OF LATIN AMERICA 185
13.6 MIDDLE EAST 186
13.6.1 GCC COUNTRIES 188
13.6.1.1 Saudi Arabia 190
13.6.1.2 UAE 191
13.6.1.3 Rest of GCC Countries 193
13.6.2 REST OF MIDDLE EAST 194
13.7 AFRICA 196

14 COMPETITIVE LANDSCAPE 198

14.1 INTRODUCTION 198
14.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 198
14.3 REVENUE ANALYSIS, 2023–2025 199
14.4 MARKET SHARE ANALYSIS, 2025 201
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 203
14.5.1 STARS 203
14.5.2 EMERGING LEADERS 203
14.5.3 PERVASIVE PLAYERS 203
14.5.4 PARTICIPANTS 203
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 205
14.5.5.1 Company footprint 205
14.5.5.2 Region footprint 206
14.5.5.3 Cell source footprint 207
14.5.5.4 Type footprint 208
14.5.5.5 Therapeutic application footprint 209
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 210
14.6.1 PROGRESSIVE COMPANIES 210
14.6.2 RESPONSIVE COMPANIES 210
14.6.3 DYNAMIC COMPANIES 210
14.6.4 STARTING BLOCKS 210
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 212
14.6.5.1 List of key startups/SMEs 212
14.6.5.2 Competitive benchmarking of key startups/SMEs 213
14.7 COMPANY VALUATION & FINANCIAL METRICS 213
14.7.1 FINANCIAL METRICS 214
14.7.2 COMPANY VALUATION 214
14.8 BRAND/PRODUCT COMPARISON 215
14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 215
14.9 COMPETITIVE SCENARIO 216
14.9.1 PRODUCT LAUNCHES 216
14.9.2 DEALS 217

15 COMPANY PROFILES 218

15.1 KEY PLAYERS 218
15.1.1 VERICEL CORPORATION 218
15.1.1.1 Business overview 218
15.1.1.2 Products offered 219
15.1.1.3 Recent developments 220
15.1.1.3.1 Product Approval 220
15.1.1.4 MnM view 220
15.1.1.4.1 Key strengths 220
15.1.1.4.2 Strategic choices 220
15.1.1.4.3 Weaknesses & competitive threats 220
15.1.2 MESOBLAST 221
15.1.2.1 Business overview 221
15.1.2.2 Products offered 222
15.1.2.3 Recent developments 223
15.1.2.3.1 Product approval 223
15.1.2.4 MnM view 223
15.1.2.4.1 Key strengths 223
15.1.2.4.2 Strategic choices 223
15.1.2.4.3 Weaknesses & competitive threats 224
15.1.3 JCR PHARMACEUTICALS CO., LTD. 225
15.1.3.1 Business overview 225
15.1.3.2 Products offered 226
15.1.3.3 Product pipeline 227

15.1.3.4 MnM view 227
15.1.3.4.1 Key strengths 227
15.1.3.4.2 Strategic choices 227
15.1.3.4.3 Weaknesses & competitive threats 227
15.1.4 MEDIPOST 228
15.1.4.1 Business overview 228
15.1.4.2 Products offered 229
15.1.4.3 Recent developments 229
15.1.4.3.1 Deals 229
15.1.4.3.2 OTHER DEVELOPMENTS 230
15.1.4.4 MnM view 230
15.1.4.4.1 Key strengths 230
15.1.4.4.2 Strategic choices 230
15.1.4.4.3 Weaknesses & competitive threats 231
15.1.5 CO.DON GMBH 232
15.1.5.1 Business overview 232
15.1.5.2 Products offered 232
15.1.5.3 MnM view 233
15.1.5.3.1 Key strengths 233
15.1.5.3.2 Strategic choices 233
15.1.5.3.3 Weaknesses & competitive threats 233
15.1.6 SMITH+NEPHEW 234
15.1.6.1 Business overview 234
15.1.6.2 Products offered 235
15.1.7 ANTEROGEN CO., LTD. 236
15.1.7.1 Business overview 236
15.1.7.2 Products offered 236
15.1.8 CORESTEMCHEMON INC. 237
15.1.8.1 Business overview 237
15.1.8.2 Products offered 238
15.1.9 VERTEX PHARMACEUTICALS INCORPORATED 239
15.1.9.1 Business overview 239
15.1.9.2 Products offered 240
15.1.9.2.1 Other developments 240
15.1.10 PHARMICELL CO., LTD 241
15.1.10.1 Business overview 241
15.1.10.2 Products offered 241
15.1.10.3 Recent developments 242
15.1.10.3.1 Deals 242
15.1.11 HOLOSTEM TERAPIE AVANZATE SRL 243
15.1.11.1 Business overview 243
15.1.11.2 Products offered 243
15.1.12 STEMPEUTICS RESEARCH PVT LTD. 244
15.1.12.1 Business overview 244
15.1.12.2 Products offered 244
15.1.12.3 Recent developments 245
15.1.12.3.1 Deals 245
15.1.13 CIPLA LIMITED 246
15.1.13.1 Business overview 246
15.1.13.2 Products offered 247
15.1.13.3 Recent developments 248
15.1.13.3.1 Product Launch 248
15.1.13.3.2 Deals 248
15.1.14 BAYER AG 249
15.1.14.1 Business overview 249
15.1.14.2 Products offered 250
15.1.14.2.1 OTHER DEVELOPMENTS 251
15.1.15 ASPEN NEUROSCIENCE 252
15.1.15.1 Business overview 252
15.1.15.2 Products offered 252
15.1.15.2.1 Other developments 252
15.1.16 LONGEVERON 253
15.1.16.1 Business overview 253
15.1.16.2 Products offered 254
15.1.16.2.1 Other developments 254
15.2 OTHER PLAYERS 255
15.2.1 ATHERSYS, INC. 255
15.2.2 BIORESTORATIVE THERAPIES, INC. 255
15.2.3 KANGSTEM BIOTECH CO., LTD. 256
15.2.4 HOPE BIOSCIENCES 256
15.2.5 CELLULAR BIOMEDICINE GROUP 257
15.2.6 PERSONALIZED STEM CELLS 257
15.2.7 CHIESI FARMACEUTICI S.P.A. 258
15.2.8 CELL TECH PHARMED 258
15.2.9 SUMITOMO PHARMA 259
15.2.10 CYNATA THERAPEUTICS 260

16 RESEARCH METHODOLOGY 261

16.1 RESEARCH DATA 261
16.1.1 SECONDARY DATA 262
16.1.2 PRIMARY DATA 262
16.2 MARKET ESTIMATION METHODOLOGY 264
16.2.1 MARKET SIZE ESTIMATION 264
16.2.2 INSIGHTS OF PRIMARY EXPERTS 266
16.2.3 TOP-DOWN APPROACH 267
16.3 MARKET GROWTH RATE PROJECTIONS 268
16.4 MARKET BREAKDOWN AND DATA TRIANGULATION 270
16.5 RESEARCH ASSUMPTIONS 271
16.6 RESEARCH LIMITATIONS 271
16.7 RISK ASSESSMENT 272

17 APPENDIX 273

17.1 DISCUSSION GUIDE 273
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277
17.3 CUSTOMIZATION OPTIONS 279
17.4 RELATED REPORTS 279
17.5 AUTHOR DETAILS 280

LIST OF TABLES

TABLE 1 STEM CELL THERAPY MARKET: IMPACT OF PORTER’S FIVE FORCES 45
TABLE 2 STEM CELL THERAPY MARKET: IMPACT OF PORTER’S FIVE FORCES 53
TABLE 3 STEM CELL THERAPY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 59
TABLE 4 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2025 59
TABLE 5 INDICATIVE SELLING PRICE, BY REGION, 2025 60
TABLE 6 STEM CELL THERAPY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 61
TABLE 7 MESOBLAST IMPROVES OUTCOMES IN STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE THROUGH MSC-BASED THERAPY 63
TABLE 8 BLUEROCK THERAPEUTICS ADVANCES REGENERATIVE TREATMENT FOR PARKINSON’S DISEASE USING STEM CELL-DERIVED NEURONS 64
TABLE 9 US-ADJUSTED RECIPROCAL TARIFF RATES 64
TABLE 10 SUPPLY CHAIN ANALYSIS: ROLE OF COMMERCIAL-SCALE/KEY MANUFACTURERS 69
TABLE 11 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS 69
TABLE 12 KEY CDMO CAPACITY ADDITIONS 70
TABLE 13 KEY SPONSOR CAPACITY ADDITIONS 71
TABLE 14 GLOBAL KEY STEM CELL THERAPY PRODUCT SALES (USD MN) 72
TABLE 15 KEY PIPELINE PRODUCTS IN STEM CELL THERAPY MARKET (AS OF 2025) 75
TABLE 16 KEY STEM CELL THERAPY PIPELINE CANDIDATES & INDICATION EXPANSIONS 75
TABLE 17 DISCONTINUED/DEPRIORITIZED STEM CELL THERAPY PIPELINE CANDIDATES 76
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN STEM CELL THERAPY MARKET 78
TABLE 19 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN STEM CELL THERAPY MARKET 79
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 83
TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 83
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 89
TABLE 25 KEY BUYING CRITERIA, BY END USER 90
TABLE 26 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024-2035 (USD MILLION) 94
TABLE 27 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2024-2035 (USD MILLION) 95
TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 95
TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS,
BY COUNTRY, 2024-2035 (USD MILLION) 95
TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 96
TABLE 31 LATIN AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 96
TABLE 32 MIDDLE EAST: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 96
TABLE 33 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 97
TABLE 34 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2024-2035 (USD MILLION) 97
TABLE 35 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 98
TABLE 36 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS,
BY COUNTRY, 2024-2035 (USD MILLION) 98
TABLE 37 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 98
TABLE 38 LATIN AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 99
TABLE 39 MIDDLE EAST: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 99
TABLE 40 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 99
TABLE 41 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2024-2035 (USD MILLION) 100
TABLE 42 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 100
TABLE 43 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 101
TABLE 44 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL
CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 101
TABLE 45 LATIN AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL
CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 101
TABLE 46 MIDDLE EAST: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL
CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 102
TABLE 47 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL
CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 102
TABLE 48 STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS,
BY REGION, 2024-2035 (USD MILLION) 103
TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 103
TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 103
TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 104
TABLE 52 LATIN AMERICA: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 104
TABLE 53 MIDDLE EAST: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 104
TABLE 54 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 105
TABLE 55 STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY REGION,
2024-2035 (USD MILLION) 105
TABLE 56 NORTH AMERICA: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 106
TABLE 57 EUROPE: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS,
BY COUNTRY, 2024-2035 (USD MILLION) 106
TABLE 58 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS,
BY COUNTRY, 2024-2035 (USD MILLION) 106
TABLE 59 LATIN AMERICA: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS,
BY COUNTRY, 2024-2035 (USD MILLION) 107
TABLE 60 MIDDLE EAST: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS,
BY COUNTRY, 2024-2035 (USD MILLION) 107
TABLE 61 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS,
BY COUNTRY, 2024-2035 (USD MILLION) 107
TABLE 62 STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY REGION, 2024-2035 (USD MILLION) 108
TABLE 63 NORTH AMERICA: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 108
TABLE 64 EUROPE: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS,
BY COUNTRY, 2024-2035 (USD MILLION) 109
TABLE 65 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 109
TABLE 66 LATIN AMERICA: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 109
TABLE 67 MIDDLE EAST: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 110
TABLE 68 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 110
TABLE 69 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION
2024-2035 (USD MILLION) 110
TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2024-2035 (USD MILLION) 111
TABLE 71 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2024-2035 (USD MILLION) 111
TABLE 72 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2024-2035 (USD MILLION) 111
TABLE 73 LATIN AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2024-2035 (USD MILLION) 112
TABLE 74 MIDDLE EAST: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2024-2035 (USD MILLION) 112
TABLE 75 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 20240.02035 (USD MILLION) 112
TABLE 76 STEM CELL THERAPY MARKET, BY TYPE, 2024- 2035 (USD MILLION) 114
TABLE 77 STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY REGION, 2024-2035 (USD MILLION) 114
TABLE 78 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 115
TABLE 79 EUROPE: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 115
TABLE 80 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 115
TABLE 81 LATIN AMERICA: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 116
TABLE 82 MIDDLE EAST: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 116
TABLE 83 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 116
TABLE 84 STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY,
BY REGION, 2024-2035 (USD MILLION) 117
TABLE 85 NORTH AMERICA: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 117
TABLE 86 EUROPE: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 118
TABLE 87 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 118
TABLE 88 LATIN AMERICA: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 118
TABLE 89 MIDDLE EAST: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 119
TABLE 90 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 119
TABLE 91 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 121
TABLE 92 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2024–2035 (USD MILLION) 122
TABLE 93 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 122
TABLE 94 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS,
BY COUNTRY, 2024–2035 (USD MILLION) 122
TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 123
TABLE 96 LATIN AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 123
TABLE 97 MIDDLE EAST: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 123
TABLE 98 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 124
TABLE 99 STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY REGION,
2024–2035 (USD MILLION) 124
TABLE 100 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES,
BY COUNTRY, 2024–2035 (USD MILLION) 125
TABLE 101 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES,
BY COUNTRY, 2024–2035 (USD MILLION) 125
TABLE 102 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES,
BY COUNTRY, 2024–2035 (USD MILLION) 125
TABLE 103 LATIN AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES,
BY COUNTRY, 2024–2035 (USD MILLION) 126
TABLE 104 MIDDLE EAST: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES,
BY COUNTRY, 2024–2035 (USD MILLION) 126
TABLE 105 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES,
BY COUNTRY, 2024–2035 (USD MILLION) 126
TABLE 106 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2024–2035 (USD MILLION) 127
TABLE 107 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 127
TABLE 108 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 128
TABLE 109 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 128
TABLE 110 LATIN AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 128
TABLE 111 MIDDLE EAST: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 129
TABLE 112 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 129
TABLE 113 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2035 (USD MILLION) 130
TABLE 114 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 130
TABLE 115 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2035 (USD MILLION) 130
TABLE 116 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2035 (USD MILLION) 131
TABLE 117 LATIN AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 131
TABLE 118 MIDDLE EAST: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 131
TABLE 119 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 132
TABLE 120 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2035 (USD MILLION) 132
TABLE 121 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 133
TABLE 122 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2035 (USD MILLION) 133
TABLE 123 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2035 (USD MILLION) 133
TABLE 124 LATIN AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 134
TABLE 125 MIDDLE EAST: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2024–2035 (USD MILLION) 134
TABLE 126 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 134
TABLE 127 STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES,
BY REGION, 2024–2035 (USD MILLION) 135
TABLE 128 NORTH AMERICA: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 135
TABLE 129 EUROPE: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 136
TABLE 130 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 136
TABLE 131 LATIN AMERICA: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 136
TABLE 132 MIDDLE EAST: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 137
TABLE 133 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 137
TABLE 134 STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS,
BY REGION, 2024–2035 (USD MILLION) 137
TABLE 135 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 138
TABLE 136 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 138
TABLE 137 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 138
TABLE 138 LATIN AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 139
TABLE 139 MIDDLE EAST: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 139
TABLE 140 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 139
TABLE 141 STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 141
TABLE 142 STEM CELL THERAPY MARKET FOR HOSPITALS, BY REGION,
2024–2035 (USD MILLION) 141
TABLE 143 NORTH AMERICA: STEM CELL THERAPY MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2035 (USD MILLION) 142
TABLE 144 EUROPE: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2024–2035 (USD MILLION) 142
TABLE 145 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2024–2035 (USD MILLION) 142
TABLE 146 LATIN AMERICA: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 143
TABLE 147 MIDDLE EAST: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 143
TABLE 148 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 143
TABLE 149 STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY REGION, 2024–2035 (USD MILLION) 144
TABLE 150 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 144
TABLE 151 EUROPE: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS,
BY COUNTRY, 2024–2035 (USD MILLION) 145
TABLE 152 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 145
TABLE 153 LATIN AMERICA: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 145
TABLE 154 MIDDLE EAST: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 146
TABLE 155 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 146
TABLE 156 STEM CELL THERAPY MARKET FOR OTHER END USERS, BY REGION,
2024–2035 (USD MILLION) 147
TABLE 157 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD MILLION) 147
TABLE 158 EUROPE: STEM CELL THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2035 (USD MILLION) 147
TABLE 159 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD MILLION) 148
TABLE 160 LATIN AMERICA: STEM CELL THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD MILLION) 148
TABLE 161 MIDDLE EAST: STEM CELL THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD MILLION) 148
TABLE 162 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD MILLION) 149
TABLE 163 STEM CELL THERAPY MARKET, BY REGION, 2024–2035 (USD MILLION) 151
TABLE 164 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY,
2024–2035 (USD MILLION) 152
TABLE 165 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 153
TABLE 166 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 153
TABLE 167 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 153
TABLE 168 NORTH AMERICA: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 154
TABLE 169 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 154
TABLE 170 US: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 154
TABLE 171 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 155
TABLE 172 US: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 155
TABLE 173 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 156
TABLE 174 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 156
TABLE 175 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 156
TABLE 176 CANADA: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 157
TABLE 177 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 158
TABLE 178 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 158
TABLE 179 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 158
TABLE 180 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 159
TABLE 181 EUROPE: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 159
TABLE 182 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 160
TABLE 183 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 160
TABLE 184 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 161
TABLE 185 GERMANY: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 161
TABLE 186 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 162
TABLE 187 UK: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 162
TABLE 188 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 162
TABLE 189 UK: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 163
TABLE 190 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 163
TABLE 191 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 163
TABLE 192 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 164
TABLE 193 FRANCE: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 164
TABLE 194 ITALY: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 165
TABLE 195 ITALY: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 165
TABLE 196 ITALY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 165
TABLE 197 ITALY: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 166
TABLE 198 SPAIN: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 166
TABLE 199 SPAIN: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 166
TABLE 200 SPAIN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 167
TABLE 201 SPAIN: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 167
TABLE 202 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 168
TABLE 203 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 168
TABLE 204 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC
APPLICATION, 2024–2035 (USD MILLION) 168
TABLE 205 REST OF EUROPE: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 169
TABLE 206 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY COUNTRY,
2024–2035 (USD MILLION) 169
TABLE 207 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 170
TABLE 208 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 170
TABLE 209 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 170
TABLE 210 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 171
TABLE 211 CHINA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 171
TABLE 212 CHINA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 171
TABLE 213 CHINA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 172
TABLE 214 CHINA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 172
TABLE 215 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 173
TABLE 216 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 173
TABLE 217 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 173
TABLE 218 JAPAN: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 174
TABLE 219 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 174
TABLE 220 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 174
TABLE 221 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 175
TABLE 222 INDIA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 175
TABLE 223 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 176
TABLE 224 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 176
TABLE 225 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 176
TABLE 226 SOUTH KOREA: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 177
TABLE 227 AUSTRALIA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 177
TABLE 228 AUSTRALIA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 177
TABLE 229 AUSTRALIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 178
TABLE 230 AUSTRALIA: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 178
TABLE 231 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 179
TABLE 232 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 179
TABLE 233 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 179
TABLE 234 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 180
TABLE 235 LATIN AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY,
2024–2035 (USD MILLION) 180
TABLE 236 LATIN AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 180
TABLE 237 LATIN AMERICA: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 181
TABLE 238 LATIN AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 181
TABLE 239 LATIN AMERICA: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 181
TABLE 240 BRAZIL: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 182
TABLE 241 BRAZIL: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 182
TABLE 242 BRAZIL: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 183
TABLE 243 BRAZIL: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 183
TABLE 244 MEXICO: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 184
TABLE 245 MEXICO: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 184
TABLE 246 MEXICO: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 184
TABLE 247 MEXICO: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 185
TABLE 248 REST OF LATIN AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 185
TABLE 249 REST OF LATIN AMERICA: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 185
TABLE 250 REST OF LATIN AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 186
TABLE 251 REST OF LATIN AMERICA: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 186
TABLE 252 MIDDLE EAST: STEM CELL THERAPY MARKET, BY COUNTRY,
2024–2035 (USD MILLION) 186
TABLE 253 MIDDLE EAST: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 187
TABLE 254 MIDDLE EAST: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 187
TABLE 255 MIDDLE EAST: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 187
TABLE 256 MIDDLE EAST: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 188
TABLE 257 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY COUNTRY,
2024–2035 (USD MILLION) 188
TABLE 258 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 188
TABLE 259 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 189
TABLE 260 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 189
TABLE 261 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 189
TABLE 262 SAUDI ARABIA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 190
TABLE 263 SAUDI ARABIA: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 190
TABLE 264 SAUDI ARABIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 191
TABLE 265 SAUDI ARABIA: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 191
TABLE 266 UAE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 192
TABLE 267 UAE: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 192
TABLE 268 UAE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 192
TABLE 269 UAE: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 193
TABLE 270 REST OF GCC: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 193
TABLE 271 REST OF GCC: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 193
TABLE 272 REST OF GCC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 194
TABLE 273 REST OF GCC: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 194
TABLE 274 REST OF MIDDLE EAST: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 195
TABLE 275 REST OF MIDDLE EAST: STEM CELL THERAPY MARKET, BY TYPE,
2024–2035 (USD MILLION) 195
TABLE 276 REST OF MIDDLE EAST: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 195
TABLE 277 REST OF MIDDLE EAST: STEM CELL THERAPY MARKET, BY END USER,
2024–2035 (USD MILLION) 196
TABLE 278 AFRICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2024–2035 (USD MILLION) 196
TABLE 279 AFRICA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 196
TABLE 280 AFRICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2024–2035 (USD MILLION) 197
TABLE 281 AFRICA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 197
TABLE 282 STRATEGIES ADOPTED BY KEY PLAYERS IN STEM CELL THERAPY
MARKET, 2023−2026 198
TABLE 283 STEM CELL THERAPY MARKET: DEGREE OF COMPETITION 202
TABLE 284 STEM CELL THERAPY MARKET: REGION FOOTPRINT 206
TABLE 285 STEM CELL THERAPY MARKET: CELL SOURCE FOOTPRINT 207
TABLE 286 STEM CELL THERAPY MARKET: TYPE FOOTPRINT 208
TABLE 287 STEM CELL THERAPY MARKET: THERAPEUTIC APPLICATION FOOTPRINT 209
TABLE 288 STEM CELL THERAPY MARKET: KEY STARTUPS/SMES 212
TABLE 289 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUPS/SMES 213
TABLE 290 STEM CELL THERAPY MARKET: PRODUCT LAUNCHES/APPROVALS,
JANUARY 2023–MAY 2026 216
TABLE 291 STEM CELL THERAPY MARKET: DEALS, JANUARY 2023–MAY 2026 217
TABLE 292 VERICEL CORPORATION: COMPANY OVERVIEW 218
TABLE 293 VERICEL CORPORATION: PRODUCTS OFFERED 219
TABLE 294 VERICEL CORPORATION: PRODUCT APPROVAL, JANUARY 2023–MAY 2026 220
TABLE 295 MESOBLAST: COMPANY OVERVIEW 221
TABLE 296 MESOBLAST: PRODUCTS OFFERED 222
TABLE 297 MESOBLAST: PRODUCTS PIPELINE 222
TABLE 298 MESOBLAST: PRODUCT APPROVAL, JANUARY 2023–MAY 2026 223
TABLE 299 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW 225
TABLE 300 JCR PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED 226
TABLE 301 MEDIPOST: COMPANY OVERVIEW 228
TABLE 302 MEDIPOST: PRODUCTS OFFERED 229
TABLE 303 MEDIPOST: PRODUCT PIPELINE 229
TABLE 304 MEDIPOST: DEALS, JANUARY 2023–MAY 2026 229
TABLE 305 MEDIPOST: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 230
TABLE 306 CO.DON GMBH: COMPANY OVERVIEW 232
TABLE 307 CO.DON GMBH: PRODUCTS OFFERED 232
TABLE 308 SMITH+NEPHEW: COMPANY OVERVIEW 234
TABLE 309 SMITH+NEPHEW: PRODUCTS OFFERED 235
TABLE 310 ANTEROGEN CO., LTD.: COMPANY OVERVIEW 236
TABLE 311 ANTEROGEN CO., LTD.: PRODUCTS OFFERED 236
TABLE 312 CORESTEMCHEMON INC.: COMPANY OVERVIEW 237
TABLE 313 CORESTEMCHEMON INC.: PRODUCTS OFFERED 238
TABLE 314 CORESTEMCHEMON INC: PRODUCT PIPELINE 238
TABLE 315 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY OVERVIEW 239
TABLE 316 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCTS PIPELINE 240
TABLE 317 VERTEX PHARMACEUTICALS INCORPORATED: OTHER DEVELOPMENTS,
JANUARY 2023–MAY 2026 240
TABLE 318 PHARMICELL CO., LTD: COMPANY OVERVIEW 241
TABLE 319 PHARMICELL CO., LTD: PRODUCTS OFFERED 241
TABLE 320 PHARMICELL CO., LTD: PRODUCT PIPELINE 242
TABLE 321 PHARMICELL CO., LTD: DEALS, JANUARY 2023–MAY 2026 242
TABLE 322 HOLOSTEM TERAPIE AVANZATE SRL: COMPANY OVERVIEW 243
TABLE 323 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCTS OFFERED 243
TABLE 324 STEMPEUTICS RESEARCH PVT LTD.: COMPANY OVERVIEW 244
TABLE 325 STEMPEUTICS RESEARCH PVT LTD.: PRODUCTS OFFERED 244
TABLE 326 STEMPEUTICS RESEARCH PVT LTD.: PRODUCT PIPELINE 245
TABLE 327 STEMPEUTICS RESEARCH PVT LTD.: DEALS, JANUARY 2023–MAY 2026 245
TABLE 328 CIPLA LIMITED: COMPANY OVERVIEW 246
TABLE 329 CIPLA LIMITED: PRODUCTS OFFERED 247
TABLE 330 CIPLA LIMITED: PRODUCT LAUNCH, JANUARY 2023–MAY 2026 248
TABLE 331 CIPLA LIMITED: DEALS, JANUARY 2023–MAY 2026 248
TABLE 332 BAYER AG: COMPANY OVERVIEW 249
TABLE 333 BAYER AG: PRODUCTS PIPELINE 250
TABLE 334 BAYER AG: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 251
TABLE 335 ASPEN NEUROSCIENCE: COMPANY OVERVIEW 252
TABLE 336 ASPEN NEUROSCIENCE: PRODUCTS PIPELINE 252
TABLE 337 ASPEN NEUROSCIENCE: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 252
TABLE 338 LONGEVERON: COMPANY OVERVIEW 253
TABLE 339 LONGEVERON: PRODUCTS PIPELINE 254
TABLE 340 LONGEVERON: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 254
TABLE 341 ATHERSYS, INC.: COMPANY OVERVIEW 255
TABLE 342 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW 255
TABLE 343 KANGSTEM BIOTECH CO., LTD.: COMPANY OVERVIEW 256
TABLE 344 HOPE BIOSCIENCES: COMPANY OVERVIEW 256
TABLE 345 CELLULAR BIOMEDICINE GROUP: COMPANY OVERVIEW 257
TABLE 346 PERSONALIZED STEM CELLS: COMPANY OVERVIEW 257
TABLE 347 CHIESI FARMACEUTICI S.P.A.: COMPANY OVERVIEW 258
TABLE 348 CELL TECH PHARMED: COMPANY OVERVIEW 258
TABLE 349 SUMITOMO PHARMA: COMPANY OVERVIEW 259
TABLE 350 CYNATA THERAPEUTICS: COMPANY OVERVIEW 260
TABLE 351 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 269

LIST OF FIGURES

FIGURE 1 STEM CELL THERAPY MARKET SEGMENTATION & REGIONAL SCOPE 31
FIGURE 2 STEM CELL THERAPY MARKET: YEARS CONSIDERED 32
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 36
FIGURE 4 GLOBAL STEM CELL THERAPY MARKET, 2024–2035 36
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN STEM CELL
THERAPY MARKET, 2023–2026 37
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF STEM CELL THERAPY MARKET 38
FIGURE 7 HIGH-GROWTH SEGMENTS IN STEM CELL THERAPY MARKET, 2026–2035 39
FIGURE 8 EUROPE TO REGISTER HIGHEST CAGR IN STEM CELL THERAPY MARKET
DURING FORECAST PERIOD 40
FIGURE 9 RISING UNMET MEDICAL NEEDS IN RARE, CHRONIC, AND DEGENERATIVE DISEASES ACCELERATING GROWTH OF STEM CELL THERAPY MARKET 41
FIGURE 10 ALLOGENEIC STEM CELL THERAPY SEGMENT ACCOUNTED FOR
LARGEST MARKET SHARE IN NORTH AMERICA 42
FIGURE 11 UK TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 42
FIGURE 12 AUTOLOGUS STEM CELL THERAPY TO DOMINATE MARKET IN 2026 43
FIGURE 13 STEM CELL THERAPY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 44
FIGURE 14 STEM CELL THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 52
FIGURE 15 STEM CELL THERAPY PRODUCTS MARKET: VALUE CHAIN ANALYSIS 57
FIGURE 16 STEM CELL THERAPY MARKET: ECOSYSTEM ANALYSIS 58
FIGURE 17 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT (2025) 60
FIGURE 18 INDICATIVE SELLING PRICE, BY REGION (2025) 60
FIGURE 19 STEM CELL THERAPY MARKET: TRENDS/DISRUPTIONS
IMPACTING CUSTOMER BUSINESS 62
FIGURE 20 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 63
FIGURE 21 STEM CELL THERAPY MARKET: SUPPLY CHAIN ANALYSIS 68
FIGURE 22 IMPACT OF AI/GEN AI ON STEM CELL THERAPY MARKET 77
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 89
FIGURE 24 KEY BUYING CRITERIA, BY END USER 89
FIGURE 25 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 152
FIGURE 26 EUROPE: STEM CELL THERAPY MARKET SNAPSHOT 157
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN STEM CELL THERAPY
MARKET, 2023–2025 (USD MILLION) 200
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN STEM CELL
THERAPY MARKET (2025) 201
FIGURE 29 STEM CELL THERAPY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 204
FIGURE 30 STEM CELL THERAPY MARKET: COMPANY FOOTPRINT 205
FIGURE 31 STEM CELL THERAPY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2025 211
FIGURE 32 EV/EBITDA OF KEY VENDORS 214

FIGURE 33 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK
BETA OF KEY VENDORS 214
FIGURE 34 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT 215
FIGURE 35 VERICEL CORPORATION: COMPANY SNAPSHOT (2025) 219
FIGURE 36 MESOBLAST: COMPANY SNAPSHOT (2025) 221
FIGURE 37 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2024) 226
FIGURE 38 MEDIPOST: COMPANY SNAPSHOT (2023) 228
FIGURE 39 SMITH+NEPHEW: COMPANY SNAPSHOT (2025) 235
FIGURE 40 CORESTEMCHEMON INC.: COMPANY SNAPSHOT (2022) 237
FIGURE 41 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT (2025) 240
FIGURE 42 CIPLA LIMITED: COMPANY SNAPSHOT (2025) 247
FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2025) 250
FIGURE 44 LONGEVERON: COMPANY SNAPSHOT (2025) 254
FIGURE 45 STEM CELL THERAPY MARKET: RESEARCH DESIGN 261
FIGURE 46 STEM CELL THERAPY MARKET: BREAKDOWN OF PRIMARIES 263
FIGURE 47 STEM CELL THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 264
FIGURE 48 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE
ANALYSIS-BASED ESTIMATION), 2025 265
FIGURE 49 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF VERICEL
CORPORATION (2025) 265
FIGURE 50 MARKET SIZE VALIDATION THROUGH PRIMARY SOURCES 266
FIGURE 51 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 267
FIGURE 52 STEM CELL THERAPY MARKET GROWTH PROJECTIONS 268
FIGURE 53 STEM CELL THERAPY MARKET: DATA TRIANGULATION 270

---

---